Cancer Immunotherapy MarketSize, Share & Industry Analysis, 2026-2034By ProductBy ApplicationBy Distribution ChannelBy End-useBy Therapy

Cancer immunotherapy refers to biologic therapies that work by directing or restoring the immune system's own ability to identify and destroy tumor cells, rather than attacking the tumor directly as chemotherapy or radiation does. The category spans monoclonal antibodies including checkpoint inhibitors, immunomodulators such as cytokine and adjuvant based agents, oncolytic viral therapies, and cancer vaccines, delivered mainly by infusion or injection in a clinical setting. Buyers are hospital and specialty oncology pharmacies, cancer research and treatment centers, and the payers and health systems that reimburse a patient's treatment course.

The global cancer immunotherapy market stood at USD 145 billion in 2025. A forecast-period rate of 14.5% takes it to USD 483.04 billion by 2034, and the study reports every year in between, passing USD 78 billion in 2020, USD 128.06 billion in 2024, USD 163.5 billion in 2026 and USD 281.03 billion in 2030.

67.7% of 2025 revenue sits in Monoclonal Antibodies, worth USD 98.17 billion and rising to USD 289.82 billion at 60% by 2034, the largest product line in both years. Growth is fastest in Oncolytic Viral Therapies at 20.21% and slowest in Monoclonal Antibodies at 12.96%. The lines gaining share are Immunomodulators, Oncolytic Viral Therapies and Cancer Vaccines. Monoclonal Antibodies lose share without losing revenue.

By application, Lung Cancer accounts for 28% of 2025 revenue at USD 40.6 billion, reaching USD 125.59 billion and 26% by 2034. Pancreatic Cancer grows faster at 19.58% against 13.36%, moving from 4% of revenue to 6% by 2034. This axis divides the same revenue as the product split rather than adding to it, so the two are read together rather than summed.

USD 63.95 billion of 2025 revenue is generated in North America, 44.1% of the global total and the largest regional share; it reaches USD 188.39 billion by 2034. Europe is next at 23.6% and USD 34.22 billion, and Middle East and Africa last at 4.4%. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

Behind these figures sit five regions, four product lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 145 billion in 2025 to USD 483.04 billion in 2034, a compound annual rate of 14.5%, having reached USD 128.06 billion in 2024 from USD 78 billion in 2020.
• The largest line by product is Monoclonal Antibodies, worth USD 98.17 billion and 67.7% of revenue in 2025, rising to USD 289.82 billion and 60% by 2034.
• At 20.21%, Oncolytic Viral Therapies grows faster than any other product line, moving from USD 8.41 billion and 5.8% of revenue in 2025 to USD 43.47 billion and 9% in 2034.
• Scenario range for 2034 runs from USD 434.74 billion in the bear case to USD 541 billion in the bull case, against a base-case USD 483.04 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 63.95 billion in 2025 (44.1% of the global total) and USD 188.39 billion by 2034, ahead of Europe at 23.6%.
• The United States accounts for 85% of North America in the base year, worth USD 54.36 billion in 2025 and reaching USD 160.13 billion by 2034, the worked country example carried through that region's chapters.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Read across the forecast period, the global cancer immunotherapy market shows movement in three places: product composition, regional weight, and the 14.5% rate applied to the whole.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Oncolytic Viral Therapies grows faster than Monoclonal Antibodies. Oncolytic Viral Therapies grows at 20.21% across 2026-2034 against 12.96% for Monoclonal Antibodies, the widest spread on the product axis. Oncolytic Viral Therapies takes its share of revenue from 5.8% to 9% while Monoclonal Antibodies gives up ground, from 67.7% to 60%. Revenue rises on both sides; USD 8.41 billion to USD 43.47 billion and USD 98.17 billion to USD 289.82 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 22.7% of revenue in 2025 to 28.5% in 2034, worth USD 32.92 billion rising to USD 137.67 billion; Latin America moves from 5.2% of revenue in 2025 to 6.5% in 2034, worth USD 7.54 billion rising to USD 31.4 billion; Middle East and Africa moves from 4.4% of revenue in 2025 to 5% in 2034, worth USD 6.37 billion rising to USD 24.14 billion. The remaining regions grow in absolute terms while giving up share: North America at 44.1% moving to 39%, Europe at 23.6% moving to 21%. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

Growth compounds at 14.5% without a step change. The market moves through USD 78 billion in 2020, USD 128.06 billion in 2024, USD 145 billion in 2025, USD 163.5 billion in 2026, USD 281.03 billion in 2030 and USD 483.04 billion in 2034. There is no discontinuity to time, and 14.5% forecast growth against 13.2% historical means the trend continues rather than turns. For a participant that makes planning a question of capturing a share of steady expansion rather than timing a discontinuity, and it is why the product and regional mixes matter more to a forecast than the headline rate does.

Oncolytic Viral Therapies adds the most incremental growth

Three sources account for the growth to 2034: 14.5% compounding across the base, share moving toward the faster product lines, and above-market expansion in the leading regions.

Downside case: USD 434.74 billion rather than USD 483.04 billion by 2034

Where the forecast could be beaten

One product line carries the market

North America holds 44.1% of the global cancer immunotherapy market in 2025, worth USD 63.95 billion on the way to USD 188.39 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 39%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Monoclonal Antibodies largest at 67.7% of 2025 revenue, Oncolytic Viral Therapies fastest at 20.21%. North America is reported axis by axis and country by country in the full study.

The largest single market in North America is the United States, at USD 54.36 billion in 2025 and USD 160.13 billion in 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 63.95 billion and USD 188.39 billion for the region, it is why this market rather than a smaller one is the one reported in full.

The product pattern in the United States is the global one: 67.7% of 2025 revenue in Monoclonal Antibodies, 60% by 2034, against 20.21% growth in Oncolytic Viral Therapies taking it from 5.8% to 9%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Per-product revenue for the United States appears on its own in the full report.

Cancer immunotherapies sold in the United States are regulated as biologics by the Food and Drug Administration, primarily through its Center for Biologics Evaluation and Research working alongside the Center for Drug Evaluation and Research for smaller-molecule immune-modulating agents. A sponsor must secure a Biologics License Application or New Drug Application before marketing, supported by clinical evidence of safety and effectiveness and by manufacturing data demonstrating current Good Manufacturing Practice compliance. Prescribing information, boxed warnings where relevant, and risk evaluation and mitigation strategies form part of the approval package. Post-market pharmacovigilance reporting continues after launch, and any change to manufacturing process or labelling requires supplemental review by the agency.

Competition in the United States runs between the suppliers this study tracks: Pfizer Inc., AstraZeneca, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Genentech, Inc (Roche), Novartis AG, Lilly, Johnson & Johnson Services, Inc, Immunocore, Ltd, Sanofi, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Amgen Inc. and Gilead Sciences, Inc.. Two different problems sit on the same axis: holding Monoclonal Antibodies at 67.7% of 2025 revenue, and taking Oncolytic Viral Therapies while it grows at 20.21%. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.

Within North America, Canada accounts for 15% of regional revenue and 6.61% of the global total, worth USD 9.59 billion in 2025 and USD 28.26 billion by 2034.

In Europe, 23.6% of global revenue puts 2025 at USD 34.22 billion with USD 101.44 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 21%, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Monoclonal Antibodies largest at 67.7% of 2025 revenue, Oncolytic Viral Therapies fastest at 20.21%. Per-axis and per-country detail for Europe sits in the full report.

USD 10.27 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 30.43 billion by 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 34.22 billion in 2025 and USD 101.44 billion in 2034, it is the country the full report breaks out in detail.

The product pattern in Germany is the global one: 67.7% of 2025 revenue in Monoclonal Antibodies, 60% by 2034, against 20.21% growth in Oncolytic Viral Therapies taking it from 5.8% to 9%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Germany by product separately.

As an European Union member state, Germany requires cancer immunotherapies to obtain marketing authorisation through the European Medicines Agency's centralised procedure, which is mandatory for advanced-therapy and most oncology biologics. The Paul-Ehrlich-Institut acts as the national competent authority for biological and immunological medicinal products, while the Federal Institute for Drugs and Medical Devices oversees conventional pharmaceuticals, both operating under the EU pharmaceutical legislation governing quality, safety, and efficacy. Manufacturers must conform to EU Good Manufacturing Practice, maintain a pharmacovigilance system, and comply with EU labelling and package leaflet requirements presented in German. Distribution also falls under the Falsified Medicines Directive's serialisation and traceability obligations.

Competition in Germany runs between the suppliers this study tracks: Pfizer Inc., AstraZeneca, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Genentech, Inc (Roche), Novartis AG, Lilly, Johnson & Johnson Services, Inc, Immunocore, Ltd, Sanofi, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Amgen Inc. and Gilead Sciences, Inc.. Two different problems sit on the same axis: holding Monoclonal Antibodies at 67.7% of 2025 revenue, and taking Oncolytic Viral Therapies while it grows at 20.21%.

The United Kingdom is sized at USD 8.21 billion in 2025, rising to USD 24.35 billion by 2034; 5.66% of global revenue and 24% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

France is sized at USD 6.84 billion in 2025, rising to USD 20.29 billion by 2034; 4.72% of global revenue and 20% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

22.7% of the global cancer immunotherapy market sits in Asia Pacific in 2025, worth USD 32.92 billion on the way to USD 137.67 billion by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

Share climbs to 28.5% by 2034, at a pace above the 14.5% global rate, which is what makes this region worth reading separately rather than scaling from the total.

The product mix reported at global level applies here, with Monoclonal Antibodies the largest line at 67.7% of 2025 revenue and Oncolytic Viral Therapies the fastest-growing at 20.21%. Per-axis and per-country detail for Asia Pacific sits in the full report.

The largest single market in Asia Pacific is China, at USD 13.83 billion in 2025 and USD 57.82 billion in 2034. Its 42% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Set against USD 32.92 billion and USD 137.67 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Demand in China follows the product mix reported at global level: Monoclonal Antibodies is the largest line at 67.7% of 2025 revenue, moving to 60% by 2034, while Oncolytic Viral Therapies grows fastest at 20.21% and takes its share from 5.8% to 9%. Because the country carries 42% of Asia Pacific, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports China by product separately.

In China, cancer immunotherapy products are regulated as biological drugs by the National Medical Products Administration, with technical review conducted through its Center for Drug Evaluation. A supplier must obtain a Drug Registration Certificate following submission of preclinical and clinical data, and manufacturing sites must hold Good Manufacturing Practice certification consistent with national standards. Imported immunotherapies additionally require import drug licensing and batch release testing before distribution. Labelling must appear in Chinese, include approved indications and storage conditions, and align with the national pharmacopoeia's specifications for biological products. Post-approval variation, adverse-event reporting, and periodic safety update submissions remain ongoing obligations under the agency's pharmacovigilance framework.

Competition in China runs between the suppliers this study tracks: Pfizer Inc., AstraZeneca, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Genentech, Inc (Roche), Novartis AG, Lilly, Johnson & Johnson Services, Inc, Immunocore, Ltd, Sanofi, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Amgen Inc. and Gilead Sciences, Inc.. Volume sits in Monoclonal Antibodies at 67.7% of 2025 revenue; movement sits in Oncolytic Viral Therapies at 20.21% growth.

5.45% of global revenue is generated in Japan; USD 7.9 billion in 2025, reaching USD 33.04 billion in 2034, and 24% of Asia Pacific.

2.72% of global revenue is generated in South Korea; USD 3.95 billion in 2025, reaching USD 16.52 billion in 2034, and 12% of Asia Pacific.

USD 7.54 billion of 2025 revenue is generated in Latin America, 5.2% of the global cancer immunotherapy market and reaches USD 31.4 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

By 2034 the share has moved up to 6.5%, so the region grows faster than the market's 14.5% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

The product mix reported at global level applies here, with Monoclonal Antibodies the largest line at 67.7% of 2025 revenue and Oncolytic Viral Therapies the fastest-growing at 20.21%. The full report breaks Latin America out along every axis and by country.

55% of Latin America's base-year revenue comes from Brazil; USD 4.15 billion, rising to USD 17.27 billion by 2034. It accounts for 55% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 7.54 billion in 2025 and USD 31.4 billion in 2034, it is the country the full report breaks out in detail.

The product pattern in Brazil is the global one: 67.7% of 2025 revenue in Monoclonal Antibodies, 60% by 2034, against 20.21% growth in Oncolytic Viral Therapies taking it from 5.8% to 9%. With 55% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Brazil by product separately.

Brazil's National Health Surveillance Agency, ANVISA, classifies cancer immunotherapies as biological products subject to its dedicated biological-product registration pathway rather than the generic route used for conventional pharmaceuticals. A sponsor must submit a sanitary registration dossier demonstrating quality, safety, and therapeutic efficacy, and manufacturing facilities, whether domestic or foreign, must hold current Good Manufacturing Practice certification recognised by the agency. Labelling and package inserts must be presented in Portuguese and follow ANVISA's format for prescription biologics, including storage and handling instructions given the sensitivity of these products. Ongoing pharmacovigilance reporting and periodic renewal of the sanitary registration are required to maintain market authorisation.

Pfizer Inc., AstraZeneca, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Genentech, Inc (Roche), Novartis AG, Lilly, Johnson & Johnson Services, Inc, Immunocore, Ltd, Sanofi, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Amgen Inc. and Gilead Sciences, Inc. are the suppliers covered in Brazil. Two different problems sit on the same axis: holding Monoclonal Antibodies at 67.7% of 2025 revenue, and taking Oncolytic Viral Therapies while it grows at 20.21%.

Mexico is sized at USD 2.26 billion in 2025, rising to USD 9.42 billion by 2034; 1.56% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

In Middle East and Africa, 4.4% of global revenue puts 2025 at USD 6.37 billion and reaches USD 24.14 billion by 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share rises to 5% over the forecast period, so the region grows faster than the market's 14.5% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the product split tracks the global one; 67.7% of 2025 revenue in Monoclonal Antibodies, fastest growth of 20.21% in Oncolytic Viral Therapies. The full report breaks Middle East and Africa out along every axis and by country.

USD 2.23 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 8.45 billion by 2034. At 35% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 6.37 billion and USD 24.14 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Demand in Saudi Arabia follows the product mix reported at global level: Monoclonal Antibodies is the largest line at 67.7% of 2025 revenue, moving to 60% by 2034, while Oncolytic Viral Therapies grows fastest at 20.21% and takes its share from 5.8% to 9%. Because the country carries 35% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Saudi Arabia carries its own product breakdown in the full report.

The Saudi Food and Drug Authority is the competent body governing cancer immunotherapies in Saudi Arabia, regulating them as biological medicinal products under its pharmaceutical registration framework. A supplier must obtain marketing authorisation by submitting quality, safety, and efficacy data, with manufacturing sites required to demonstrate Good Manufacturing Practice compliance recognised through the authority's inspection or reliance procedures. The Authority increasingly aligns its technical requirements with Gulf Cooperation Council harmonisation efforts, allowing mutual recognition among member states while retaining independent national approval. Arabic-language labelling, cold-chain handling instructions where applicable, and adverse-event reporting obligations to the Authority's pharmacovigilance centre apply once a product reaches the market.

Competition in Saudi Arabia runs between the suppliers this study tracks: Pfizer Inc., AstraZeneca, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Genentech, Inc (Roche), Novartis AG, Lilly, Johnson & Johnson Services, Inc, Immunocore, Ltd, Sanofi, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Amgen Inc. and Gilead Sciences, Inc.. Volume sits in Monoclonal Antibodies at 67.7% of 2025 revenue; movement sits in Oncolytic Viral Therapies at 20.21% growth.

South Africa is sized at USD 1.59 billion in 2025, rising to USD 6.04 billion by 2034; 1.1% of global revenue and 25% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Application, Distribution Channel, End-Use, Therapy, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.